Skip to main content

Table 5 Change in Rutherford class at 6 months

From: The role of amputation as an outcome measure in cellular therapy for critical limb ischemia: implications for clinical trial design

 

Improved

Worse

% Imp

Total

p *

Total

17

31

35.4%

48

 

R4

12

6

66.7%

18

0.0005

R5

5

25

16.7%

30

 

BMAC

13

21

38.2%

34

 

R4

9

2

81.8%

11

0.003

R5

4

19

17.4%

23

 

Control

4

10

28.6%

14

 

R4

3

4

42.9%

7

0.2367

R5

1

6

14.3%

7

 
  1. * p calculated using Fischer's exact test
Back to article page

Journal of Translational Medicine

ISSN: 1479-5876

Contact us